Mark Wigglesworth joined AstraZeneca in Sept 2012 to lead the newly formed Global High Throughput Screening Centre. His screening experience was gained at SmithKline Beecham and GlaxoSmithKline where he worked extensively in G-Protein coupled receptor (GPCR) drug discovery initiating and leading a number of projects to deliver lead molecules to drug discovery programmes. Mark has led groups of scientists responsible for delivery of structure activity relationship data to iterative chemistry programmes as well as working within Compound Management. Mark has worked collaboratively with several academic groups and organisations such as MRC-T, has contributed to numerous publications in the field of GPCR pharmacology and Compound Management including editing a book describing the Management of Biological and Chemical Samples for Screening Applications. In his current role he leads a team of more than 20 scientists dedicated to identifying novel chemical starting points for drug discovery programmes.